Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: A follow up report

National Medical Journal of India

Volumn 17, Issue 2, 2004, Pages 71-73

  Saikia, T K ^a   Parikh, P M ^a   Tawde, S ^a   Amare Kadam, P S ^a   Rajadhyaksha, S ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LEUKOCYTE ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHRONIC DISEASE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FATALITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELOID LEUKEMIA; NAUSEA AND VOMITING; PERIPHERAL BLOOD STEM CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; SIBLING; STEM CELL TRANSPLANTATION; VEIN OCCLUSION;

ADOLESCENT; ADULT; BUSULFAN; CHILD; CHRONIC DISEASE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, CHRONIC; MALE; NEOPLASM RECURRENCE, LOCAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 2342459037     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
2. Thomas ED, Clift PA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986;104:155-163.
3. Clift RA, Radich J, Appelbaum FR, Martin P, Flowers MED, Deeg HJ, et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999;94:3960-2.
4. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic case: Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-14.
5. Gratwohl A, Hermans J, Niederweiser D, Frassoni F, Arcese W, Gahrton G, et al. Bone marrow, transplantation for chronic myeloid leukemia: Long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993;12:509-16.
6. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-92.
7. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101:441-5.
8. Das M, Saikia TK, Advani SH, Parikh PM, Tawde S. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003;32:125-9.
9. Giralt S, Sobocinski K, Horowitz MM. Impact of imatinib therapy on the use of allogeneic-hematopoietic stem cell transplant (HSCT) for the treatment of chronic myelogenous leukemia (CML). Blood 2003;102:473a.
10. Saikia TK, Advani SH, Parikh PM, Bapna A, Somjee S, Mukhopadhyay A, et al. Results of allogeneic bone marrow transplant in chronic myeloid leukemia following conditioning with busulfan and cyclophosphamide. J Assoc Physicians India 1999;47:770-3.
11. Chandy M, Srivastava A, Dennison D, Mathews V, George B. Allogeneic bone marrow transplantation in the developing world: Experience from a center in India. Bone Marrow Transplant 2001;27:785-90.
12. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly-diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
13. Hughes T, Kaeda J, Branford S, Rudzki B, Hochhaus A, Goldman JM, et al. Molecular response to imatinib (STI571) or interferon+Ara-C as initial therapy for CML: Results in the IRIS study. Blood 2002;100:93a.
14. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood 1999;94:1517-36.
15. Goldman JM, Marin D, Olavarria E, Apperley JF. Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol (2 Suppl 2) 2003;40:98-103.
16. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-8.